Short-term effects of high-dose zoledronic acid treatment on bone mineralization density distribution after orthotopic liver transplantation

Calcified Tissue International

Volumn 83, Issue 3, 2008, Pages 167-175

  Misof, B M ^a   Bodingbauer, M ^b   Roschger, P ^a   Wekerle, T ^b   Pakrah, B ^c   Haas, M ^b   Kainz, A ^b,d   Oberbauer, R ^b,d   Muhlbacher F ^b   Klaushofer, K ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^d KH Elisabethinen   (Austria)

Author keywords

Bone mineralization density distribution; High dose zoledronic acid; Liver transplantation; Quantitative backscattered electron imaging

Indexed keywords

CALCIUM; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE MINERALIZATION; CALCIUM BONE LEVEL; CLINICAL ARTICLE; CORTICAL BONE; DRUG EFFECT; DRUG MECHANISM; FEMALE; FRACTURE; HUMAN; INCIDENCE; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; TRABECULAR BONE;

ADULT; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; CALCIFICATION, PHYSIOLOGIC; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 52649109707     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-008-9161-2     Document Type: Article

References (45)

1. BA Crawford ED Labio SI Strasser GW McCaughan 2006 Vitamin D replacement for cirrhosis related bone disease Nat Clin Pract Gastroenterol Hepatol 3 689 699
2. JE Hay 2003 Osteoporosis in liver diseases and after live transplantation J Hepatol 38 856 865
3. A Monegal M Navasa N Guanabens P Peris F Pons MJ Martinez de Osaba A Rimola J Rodes J Munoz-Gomez 1997 Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation Calcif Tissue Int 60 148 154
4. MM Guichelaar M Malinchoc JD Sibonga BL Clarke JE Hay 2003 Bone histomorphometric changes after liver transplantation for chronic cholestatic liver disease J Bone Miner Res 18 2190 2109
5. G Millonig IW Graziadei D Eichler KP Pfeiffer G Finkenstedt P Muehllechner A Koenigsrainer R Margreiter W Vogel 2005 Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study Liver Transpl 11 960 966
6. GL Klein DB Endres JD Colonna II WE Berquist LI Goldstein RW Busuttil LJ Deftos 1989 Absence of hyperparathyroidism in severe liver disease Calcif Tissue Int 44 330 334
7. A Monegal M Navasa N Guanabens P Peris F Pons MJ Martinez de Osaba J Ordi A Rimola J Rodes J Munoz-Gomez 2001 Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics Osteoporos Int 12 484 492
8. TH Diamond D Stiel M Lunzer D McDowall RP Eckstein S Posen 1989 Hepatic osteodystrophy. Static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease Gastroenterology 96 213 221
9. MM Guichelaar M Malinchoc J Sibonga BL Clarke JE Hay 2002 Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry Hepatology 36 895 903
10. JE Hay KD Lindor RH Wiesner ER Dickson RA Krom NF LaRusso 1991 The metabolic bone disease of primary sclerosing cholangitis Hepatology 14 257 261
11. JA McDonald CR Dunstan P Dilworth K Sherbon AG Sheil RA Evans GW McCaughan 1991 Bone loss after liver transplantation Hepatology 14 613 619
12. MJ Guichelaar R Kendall M Malinchoc JE Hay 2006 Bone mineral density before and after OLT: long-term follow-up and predictive factors Liver Transpl 12 1390 1402
13. A Cohen P Sambrook E Shane 2004 Management of bone loss after organ transplantation J Bone Miner Res 19 1919 1932
14. E Siris 2000 Alendronate in the treatment of osteoporosis: a review of the clinical trials J Womens Health Gender-Based Med 9 599 606
15. BAL Crawford C Kam J Pavlovic K Byth DJ Handelsman PW Angus GW McCaughan 2006 Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial Ann Intern Med 144 239 248
16. M Bodingbauer T Wekerle B Pakrah G Silberhumer P Roschger M Peck-Radosavljevic S Grampp S Rockenschaub G Berlakovich R Steininger K Klaushofer R Oberbauer F Mühlbacher 2007 Prophylactic bisphosphonate treatment prevents bone fractures after liver transplantation Am J Transplant 7 1763 1769
17. G Boivin PJ Meunier 2002 Effects of bisphosphonates on matrix mineralization J Musculoskelet Neuronal Interact 2 538 543
18. B Borah TE Dufresne EL Ritman SM Jorgensen S Liu PA Chmielewski RJ Phipps X Zhou JD Sibonga RT Turner 2006 Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography Bone 39 345 352
19. A Boyde SJ Jones 1983 Backscattered electron imaging of skeletal tissues Metab Bone Dis Rel Res 5 145 150
20. P Roschger P Fratzl J Eschberger K Klaushofer 1998 Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies Bone 23 319 326
21. Currey JD (2002) Bones: structure and mechanics. Princeton University Press, Princeton, NJ, p 436
22. Fratzl P, Gupta HS, Roschger P, Klaushofer K (2008) Bone nanostructure and its relevance for mechanical performance, disease and treatment. In: Vogel V (ed) Nanotechnology-nanomedicine and nanobiotechnology, Wiley-VCH, Weinheim, Germany (in press)
23. P Roschger HS Gupta A Berzlanovich G Ittner DW Dempster P Fratzl F Cosman M Parisien R Lindsay JW Nieves K Klaushofer 2003 Constant mineralization density distribution in cancellous human bone Bone 32 316 323
24. P Roschger EP Paschalis P Fratzl K Klaushofer 2008 Bone mineralization density distribution in health and disease Bone 42 456 466
25. P Roschger S Rinnerthaler J Yates GA Rodan P Fratzl K Klaushofer 2001 Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women Bone 29 185 191
26. R Zoehrer P Roschger EP Paschalis JG Hofstaetter E Durchschlag P Fratzl R Phipps K Klaushofer 2006 Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women J Bone Miner Res 21 1106 1112
27. M Haas Z Leko-Mohr P Roschger J Kletzmayr C Schwarz C Mitterbauer R Steininger S Grampp K Klaushofer G Delling R Oberbauer 2003 Zoledronic acid to prevent bone loss in the first six months after renal transplantation Kidney Int 63 1130 1136
28. AM Parfitt MK Drezner FH Glorieux JA Kanis H Malluche PJ Meunier 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee J Bone Miner Res 2 595 610
29. Tovey FI, Stamp TCB (1995) The measurement of metabolic bone disease. Measurements in medicine series, vol 1. Parthenon Publishing Group, Carnforth, UK
30. BM Misof P Roschger F Cosman ES Kurland W Tesch P Messmer DW Dempster J Nieves E Shane P Fratzl K Klaushofer JP Bilezikian R Lindsay 2003 Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment J Clin Endocrinol Metab 88 1150 1156
31. P Roschger DW Dempster H Zhou EP Paschalis SJ Silverberg E Shane JP Bilezikian K Klaushofer 2007 New observations on bone quality in mild hyperparathyroidism as determined by quantitative backscattered electron imaging J Bone Miner Res 22 717 723
32. P Fratzl P Roschger N Fratzl-Zelman EP Paschalis R Phipps K Klaushofer 2007 Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume Calcif Tissue Int 81 73 80
33. MA Donovan D Dempster H Zhou DJ McMahon J Fleischer E Shane 2005 Low bone formation in premenopausal women with idiopathic osteoporosis J Clin Endocrinol Metab 90 3331 3336
34. Roschger P, Manjubala I, Hofstaetter JG, Shane E, Donovan MA, Fleischer J, Dempster D, Fratzl P, Klaushofer K (2005) Reduced mineralization density of bone in premenopausal women with idiopathic osteoporosis. Twenty-seventh annual meeting of the American Society for Bone and Mineral Research, Nashville, TN, September 23-27, 2005 [abstract]
35. MM Guichelaar M Malinchoc J Sibonga BL Clarke JE Hay 2004 Immunosuppressive and postoperative effects of orthotopic liver transplantation on bone metabolism Liver Transpl 10 638 647
36. S Vedi M Ninkovic NJ Garrahan GJM Alexander JE Compston 2002 Effects of a single infusion of pamidronate prior to liver transplantation: a bone histomorphometric study Transpl Int 15 290 295
37. D Ruffoni P Fratzl P Roschger K Klaushofer R Weinkamer 2007 The bone mineralization density distribution as a fingerprint of the mineralization process Bone 40 1308 1319
38. S Vedi S Greer SJ Skingle NJ Garrahan M Ninkovic GA Alexander JE Compston 1999 Mechanism of bone loss after liver transplantation: a histomorphometric analysis J Bone Miner Res 14 281 287
39. OM Crosbie R Freaney MJ McKenna MP Curry JE Hegarty 1999 Predicting bone loss following orthotopic liver transplantation Gut 44 430 434
40. PR Ebeling DB Burr 2008 Positive effects of intravenous zoledronic acid on bone remodeling and structure: are different effects on osteoblast activity to other oral bisphosphonates responsible? J Bone Miner Res 23 2 5
41. DB Burr L Miller M Grynpas L Jiliang A Boyde T Mashiba T Hirano CC Johnston 2003 Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs Bone 33 960 969
42. T Mashiba T Hirano CH Turner MR Forwood CC Johnston DB Burr 2000 Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biocmechanical properties in dog rib J Bone Miner Res 15 613 620
43. KW Lyles CS Colon-Emeric JS Magaziner JD Adachi CF Pieper C Mautalen L Hyldstrup C Recknor L Nordsletten KA Moore C Lavecchia J Zhang P Mesenbrink PK Hodgson K Abrams JJ Orloff Z Horowitz EF Eriksen S Boonen 2007 Zoledronic acid and clinical fractures and mortality after hip fracture N Engl J Med 357 1799 1809
44. DM Black PD Delmas R Eastell IR Reid S Boonen JA Cauley F Cosman P Lakatos PC Leung Z Man C Mautalen P Mesenbrink H Hu J Caminis K Tong T Rosario-Jansen J Krasnow TF Hue D Sellmeyer EF Eriksen SR Cummings 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822
45. RR Recker PD Delmas J Halse IR Reid S Boonen PA Garcia-Hernandez J Supronik EM Lewiecki L Ochoa P Miller H Hu P Mesenbrink F Hartl J Gasser EF Eriksen 2008 Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure J Bone Miner Res 23 6 16